Kaken Pharmaceutical (4521) Q3 2025 earnings summary

Executive summary

• Net sales for the nine-month period ended December 31, 2024, rose 39.0% year-over-year to ¥75,990 million, with operating profit up 186.5% to ¥25,420 million and profit attributable to owners of the parent up 187.2% to ¥19,175 million.

• Comprehensive income increased 131.7% year-over-year to ¥18,690 million for the nine-month period.

Financial highlights

• Gross profit for the nine-month period was ¥49,193 million, up from ¥29,860 million year-over-year.

• Operating profit surged to ¥25,420 million from ¥8,873 million, and ordinary profit reached ¥26,081 million from ¥9,304 million year-over-year.

• Basic earnings per share for the nine-month period was ¥506.31, compared to ¥177.10 in the prior year.

• Total assets increased to ¥193,422 million as of December 31, 2024, from ¥171,623 million as of March 31, 2024.

• Net assets rose to ¥155,259 million from ¥143,755 million over the same period.

Outlook and guidance

• Full-year forecast for fiscal year ending March 31, 2025: net sales of ¥88,500 million (up 22.8% year-over-year), operating profit of ¥20,800 million (up 118.6%), and profit attributable to owners of the parent of ¥14,200 million (up 76.9%).

• Basic earnings per share forecasted at ¥374.93 for the full year.

• No revisions to previously announced forecasts.